All In Biotech

Drug Trial Radar · NCT06750094

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Dec 12, 2024

Primary completion

Dec 15, 2027

Study completion Apr 13, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Conditions

  • Colorectal Neoplasms

Interventions

  • AmivantamabBiological

    Amivantamab will be administered.

  • CetuximabBiological

    Cetuximab will be administered.

  • BevacizumabBiological

    Bevacizumab will be administered.

  • 5-fluorouracilDrug

    5-fluorouracil will be administered as chemotherapy regimen.

  • Leucovorin calcium/LevoleucovorinDrug

    Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

  • IrinotecanDrug

    Irinotecan will be administered as chemotherapy regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 2 years 1 month
  2. Overall Survival (OS)Time frame: Up to 4 years 4 months

Locations

251 sites in 26 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Center

    Chandler, Arizona · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Arizona Oncology Associates PC NAHOA

    Prescott, Arizona · Completed

  • St. Bernard's Medical Center

    Jonesboro, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • CBCC Global Research

    Bakersfield, California · Recruiting

  • Los Angeles Cancer Network

    Glendale, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA

    Santa Monica, California · Recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Torrance Memorial Physicians Network

    Torrance, California · Recruiting

  • University of Colorado Denver Anschultz Medical Campus

    Aurora, Colorado · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Eastern Connecticut Hematology & Oncology Assoc.

    Norwich, Connecticut · Completed

  • Florida Cancer Specialists South

    Fort Myers, Florida · Recruiting

  • Mount Sinai Medical Center Campus

    Miami Beach, Florida · Completed

  • AdventHealth Cancer Institute

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists North Region

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists East

    West Palm Beach, Florida · Recruiting

  • University Cancer And Blood Center LLC

    Athens, Georgia · Recruiting

  • Grady Memorial Hospital

    Atlanta, Georgia · Recruiting

  • Piedmont Cancer Institute

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute Emory University

    Atlanta, Georgia · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • Illinois CancerCare

    Peoria, Illinois · Recruiting

  • Franciscan Health

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Mission Cancer Blood

    Waukee, Iowa · Recruiting

  • Cancer Center of Kansas

    Wichita, Kansas · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • MedStar Franklin Square Medical Center

    Baltimore, Maryland · Recruiting

  • Frederick Health Hospital - James M Stockman Cancer Institute

    Frederick, Maryland · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Cancer And Hematology Centers of Western Michigan PC

    Grand Rapids, Michigan · Recruiting

  • Hattiesburg Clinic

    Hattiesburg, Mississippi · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

Showing 40 of 251 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.